Gain Therapeutics, Inc. (Nasdaq: GANX) ('Gain”, or the 'Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule ...
Co-Founder & Chief Scientific Officer, Dr. David Vaillancourt, will serve as a key scientific leader in a $22 million ...
Parkinson’s disease is a brain disorder that gradually affects movement and many other body functions. It develops as nerve ...
A patch can deliver medicines through skin—but that does not mean every vitamin or wellness patch works. Experts explain what ...
Dr Mona Nongmeikapam I would like to start out with an apology- No, we cannot cure Alzheimer’s Disease. You cannot leave your affected family members with us to be fixed, there are no medicines yet to ...
Detailed price information for Acadia Pharmaceutica (ACAD-Q) from The Globe and Mail including charting and trades.
Acadia Pharmaceuticals announced on Thursday that its RADIANT Phase 2 trial for Alzheimer's disease psychosis missed the main ...
"It passes through our bodies, our cells and every living organism on the planet, yet we know surprisingly little about ...
The Maine Monitor on MSN
Her Alzheimer’s diagnosis took 2 years. New blood tests might help others get answers sooner
Not all insurance companies cover the tests, which help diagnose Alzheimer’s disease. But some do, and more may in the future ...
Today we highlight a discovery with potentially important implications for future Alzheimer's research and treatments. We ...
Heart and blood vessel diseases are common in people living with Alzheimer’s disease and Parkinson’s disease. Many of these ...
Citi’s Yigal Nochomovitz trimmed his price target to $33 from $40 and kept a Buy rating following the company’s update.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results